Merck KGaA's advisory board has named Karl-Ludwig Kley, the current CFO of Lufthansa, as its new CEO.

Orchid Cellmark has appointed Thomas A. Bologna as the company's new president and CEO.

Perlan Therapeutics named Sterling Johnson president and a director.

Morphotek has named Robert Radie chief business officer and promoted Dr. Luigi Grasso to senior vice president of research and development.

Amarillo Biosciences has appointed Gary W. Coy as CFO.

Inotek Pharmaceuticals has hired Emma Reeve as vice president and CFO.

Nabi Biopharmaceuticals has named Adam E. Logal interim CFO, chief accounting officer and treasurer. He replaces Mark Smith, who resigned.

Acorda Therapeutics has announced that Lorin J. Randall, senior vice president and CFO for Eximias Pharmaceutical, has become a member of the Acorda board of directors and will serve as the Chairman of Acorda's audit committee.

Seattle Genetics named Daniel F. Hoth, M.D., to the company's board of directors.

Callisto Pharmaceuticals announced that Dr. Arthur Sytkowski, associate professor of medicine at Harvard University, has agreed to serve as Callisto's clinical trial advisor and medical safety monitor.

Ventaira Pharmaceuticals has named Phyllis Gardner to its board of directors.